oral glp 1 meds GLP-1: how to win in the next GLP-1 era 1 boost Novo Nordisk's oral GLP-1 drug
Description
Do not dismiss it
They Dont Address Emotional Drivers Stress, loneliness, and trauma still need care and support
Although private insurers in Denmark have historically reimbursed Wegovy, they will stop in January 2024 due to high demand [22,23]
However, it is noteworthy that a 26-week treatment of dulaglutide 1.5 mg or tirzepatide 5 mg showed comparable outcomes in improvements of MASH and liver fibrosis biomarkers, including liver enzymes, keratin-18, procollagen III, and adiponectin
It is also a direct violation of ERISA to fail to have a proper Plan Document (ERISA 402) and a complete Summary Plan Description (ERISA 102)
